A Study of LY3316531 in Healthy Participants and in Participants With Psoriasis

I9H-MC-FFAA -

The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).

Trial Summary

Age Range
18 - 64 years
Conditions the trial is for
Psoriasis
What the trial is testing?
LY3316531-IV
Could I receive a Placebo?
Yes
Enrollment Goal
63
Trial Dates
Jan 30, 2018 - Jul 29, 2019
How long will I be in the trial?
Your participation could last between 16 and 57 weeks.
Trial Phase
I

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.